Baldwin Brothers Inc. MA Has $14.47 Million Holdings in Merck & Company, Inc. (MRK)
Baldwin Brothers Inc. MA cut its position in Merck & Company, Inc. (NYSE:MRK) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 225,800 shares of the company’s stock after selling 5,025 shares during the period. Merck & comprises about 2.3% of Baldwin Brothers Inc. MA’s portfolio, making the stock its 9th largest position. Baldwin Brothers Inc. MA’s holdings in Merck & were worth $14,472,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boston Partners grew its holdings in shares of Merck & by 2.6% in the 1st quarter. Boston Partners now owns 19,935,016 shares of the company’s stock valued at $1,266,671,000 after buying an additional 500,476 shares during the period. Clearbridge Investments LLC increased its position in shares of Merck & by 0.6% in the 1st quarter. Clearbridge Investments LLC now owns 13,414,669 shares of the company’s stock valued at $852,368,000 after buying an additional 77,344 shares in the last quarter. Sanders Capital LLC increased its position in shares of Merck & by 3.3% in the 1st quarter. Sanders Capital LLC now owns 11,593,645 shares of the company’s stock valued at $752,482,000 after buying an additional 365,276 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Merck & by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,821,563 shares of the company’s stock valued at $624,064,000 after buying an additional 41,748 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Merck & by 8.1% in the 2nd quarter. Bank of Montreal Can now owns 9,723,813 shares of the company’s stock valued at $623,199,000 after buying an additional 732,720 shares in the last quarter. Institutional investors own 72.92% of the company’s stock.
Several brokerages recently commented on MRK. BMO Capital Markets reaffirmed a “buy” rating and set a $74.00 price objective on shares of Merck & in a research note on Tuesday, June 6th. Credit Suisse Group set a $72.00 target price on Merck & and gave the stock a “buy” rating in a report on Tuesday, June 6th. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a research note on Monday, June 12th. BidaskClub raised Merck & from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Citigroup Inc. set a $65.00 price target on Merck & and gave the stock a “hold” rating in a report on Wednesday, July 5th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $70.00.
TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/baldwin-brothers-inc-ma-has-14-47-million-holdings-in-merck-company-inc-mrk/1603608.html.
Merck & Company, Inc. (MRK) traded up 0.86% during mid-day trading on Monday, hitting $64.58. The company had a trading volume of 3,303,483 shares. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The company’s 50 day moving average price is $63.52 and its 200-day moving average price is $63.68. The firm has a market capitalization of $176.13 billion, a PE ratio of 34.96 and a beta of 0.80.
Merck & (NYSE:MRK) last issued its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. During the same period in the prior year, the firm earned $0.93 earnings per share. Merck &’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.94%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is currently 76.11%.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.